About us Pricing ContactSubscribe

E

Enriqueta Felip

Vall d'Hebron Institute of OncologyORCID https://orcid.org/0000-0002-7620-0098

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

New England Journal of Medicine20159,391 citations

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

The Lancet20156,477 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

New England Journal of Medicine20186,460 citations

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

The Lancet Oncology20125,500 citations

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

The Lancet Oncology20211,333 citations

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology2012928 citationsCorresponding

Enriqueta Felip · Scinovex